We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Draft Guidance for Antimicrobial Drugs for Cytomegalovirus
FDA Issues Draft Guidance for Antimicrobial Drugs for Cytomegalovirus
Sponsors of trials for drugs to prevent cytomegalovirus (CMV) infection in transplantation should use incidence of disease within 6 to 12 months post-transplantation as their primary endpoint, according to new draft guidance from the FDA.